Prelude Therapeutics presents preclinical data on SMARCA2 and KAT6A degraders at AACR

Prelude Therapeutics Inc

PRT3789, a selective SMARCA2 degrader in Phase 1/2, shows deep SMARCA2 degradation and high selectivity over SMARCA4.
KAT6A degraders demonstrate robust anti-cancer activity in preclinical breast and lung cancer models, including complete regressions.
Prelude's KAT6A degraders show reduced hematologic toxicity compared to dual KAT6A/B inhibitors, potentially improving safety.
SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4, contributing to broad therapeutic index of PRT3789.
KAT6A degraders disrupt HAT complex and affect ERα expression, showing activity in ESR1- and PI3Kα-mutant and resistant cells.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.